These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 2975810)

  • 41. [Antiserotonergic effect of antidepressives in quipazine-induced headshake behavior in the rat].
    Fischer W; Müller M
    Pharmazie; 1984 Nov; 39(11):776-7. PubMed ID: 6531385
    [No Abstract]   [Full Text] [Related]  

  • 42. Reversal of testosterone-induced dominance by the serotonergic agonist quipazine.
    Bonson KR; Winter JC
    Pharmacol Biochem Behav; 1992 Aug; 42(4):809-13. PubMed ID: 1513863
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacological profile of a model for central serotonin receptor activation.
    Matthews WD; Smith CD
    Life Sci; 1980 Apr; 26(17):1397-403. PubMed ID: 6247593
    [No Abstract]   [Full Text] [Related]  

  • 44. Brain amine levels and competitive behavior between rats in a straight runway.
    Masur J; Czeresnia S; Skitnevsky H; Carlini EA
    Pharmacol Biochem Behav; 1974; 2(1):55-62. PubMed ID: 4275179
    [No Abstract]   [Full Text] [Related]  

  • 45. Quipazine has a biphasic effect on slow wave sleep and reduces REM sleep rebound in REM sleep deprived rats.
    Zak R; Radulovacki M
    Brain Res Bull; 1982 Mar; 8(3):329-31. PubMed ID: 7093740
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Substituted piperazines as central serotonin agonists: comparative specificity of the postsynaptic actions of quipazine and m-trifluoromethylphenylpiperazine.
    Fuller RW; Snoddy HD; Mason NR; Hemrick-Luecke SK; Clemens JA
    J Pharmacol Exp Ther; 1981 Sep; 218(3):636-41. PubMed ID: 6167711
    [No Abstract]   [Full Text] [Related]  

  • 47. Involvement of the serotonergic system in the prolongation of pentobarbital sleeping time produced by prostaglandin D2.
    Hollingsworth EB; Patrick GA
    Pharmacol Biochem Behav; 1985 Mar; 22(3):365-70. PubMed ID: 2859604
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Reduced head-twitch response to quipazine of rats previously treated with methiothepin: possible involvement of dopaminergic system.
    Dall'Olio R; Vaccheri A; Montanaro N
    Pharmacol Biochem Behav; 1985 Jul; 23(1):43-8. PubMed ID: 2994121
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The effects of quipazine and fluoxetine on extinction of a previously-reinforced operant response in rats.
    Beninger RJ
    Pharmacol Biochem Behav; 1984 Oct; 21(4):533-7. PubMed ID: 6334317
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Discriminative stimulus properties of quipazine: mediation by serotonin2 binding sites.
    Friedman RL; Barrett RJ; Sanders-Bush E
    J Pharmacol Exp Ther; 1984 Mar; 228(3):628-35. PubMed ID: 6707913
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Male dominance, serotonergic systems, and the behavioral and physiological effects of drugs in vervet monkeys (Cercopithecus aethiops sabaeus).
    Raleigh MJ; Brammer GL; McGuire MT
    Prog Clin Biol Res; 1983; 131():185-97. PubMed ID: 6316362
    [No Abstract]   [Full Text] [Related]  

  • 52. Prostaglandin D2 inhibits pentylenetetrazole-induced convulsions in rats by a serotonin-mediated mechanism.
    Bhattacharya SK; Parmar SS
    Pharm Res; 1987 Oct; 4(5):406-8. PubMed ID: 2977646
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Quipazine-induced head-twitch in mice.
    Malick JB; Doren E; Barnett A
    Pharmacol Biochem Behav; 1977 Mar; 6(3):325-9. PubMed ID: 140381
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Serotonergic stimulation of pituitary-adrenocortical activity in rats: evidence for multiple sites of action.
    Meyer JS; McElroy JF; Yehuda R; Miller J
    Life Sci; 1984 May; 34(20):1891-8. PubMed ID: 6328146
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Sleep suppressant action of quipazine: relation to central serotonergic stimulation.
    Fornal C; Radulovacki M
    Pharmacol Biochem Behav; 1981 Dec; 15(6):937-44. PubMed ID: 7323120
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Possible dopamine agonist properties of quipazine maleate.
    Feigenbaum JJ; Yanai J; Klawans HL
    Int J Neurosci; 1983; 18(3-4):205-10. PubMed ID: 6222999
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Potentiation by quipazine of adrenergic transmission in mesenteric arteries of spontaneously hypertensive rats.
    Uruno T; Su C
    Eur J Pharmacol; 1984 May; 101(1-2):69-74. PubMed ID: 6086365
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Raphe unit activity in freely moving cats: effects of quipazine.
    Trulson ME; Crisp T; Howell GA
    Neuropharmacology; 1982 Jul; 21(7):681-6. PubMed ID: 7121739
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of quipazine, a serotonin-like drug, on striatal cholinergic interneurones.
    Euvrard C; Javoy F; Herbet A; Glowinski J
    Eur J Pharmacol; 1977 Feb; 41(3):281-9. PubMed ID: 138594
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of midbrain raphe lesion or 5,7-dihydroxytryptamine treatment on the prolactin-releasing action of quipazine and D-fenfluramine in rats.
    Quattrone A; Schettini G; di Renzo G; Tedeschi G; Preziosi P
    Brain Res; 1979 Sep; 174(1):71-9. PubMed ID: 487124
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.